Candel Therapeutics Inc (CADL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.85 (-4.32%), Market cap $0.57B, 52-week low–high $4.42 ~ $8.94.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known a
Financial statements, price targets, institutional (13F) holdings and related news for Candel Therapeutics Inc are updated in real time on BlackAll Trade.
Candel Therapeutics Inc trades at $10.85 (-4.32%). Real-time quotes and charts are available on BlackAll Trade.
Candel Therapeutics Inc has a market cap of about $0.57B.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of pro